Open AccessA Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon
Author(s) -
Sally Temraz,
Fadi Nasr,
Joseph Kattan,
D Abigerges,
W. Moukadem,
Fadi Farhat,
Layal Maatouk,
Georges Chahine,
Ali Shamseddine
Publication year - 2022
Publication title -
biologics
Language(s) - English
Resource type - Journals
eISSN - 1177-5491
pISSN - 1177-5475
DOI - 10.2147/btt.s340525
Subject(s) - bevacizumab , medicine , folfox , tolerability , colorectal cancer , chemotherapy , clinical endpoint , oncology , adverse effect , regimen , chemotherapy regimen , oxaliplatin , surgery , cancer , clinical trial
When combined with chemotherapy, bevacizumab improves progression-free survival (PFS) in metastatic colorectal cancer (mCRC). This observational trial was designed to assess the safety and efficacy of bevacizumab plus first-line chemotherapy in a real-world setting in Lebanon.